Full-Time

Business Development Director

Posted on 7/4/2026

Perceptive

Perceptive

1,001-5,000 employees

Imaging core labs and eClinical solutions

No salary listed

Remote in UK

Remote

Remote within the United Kingdom.

Bachelor's, MBA

Category
Business & Strategy (1)
Required Skills
Sales
Lead Generation
Salesforce
Risk Management
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Perceptive

See people who can refer or advise you

Requirements
  • Proven track record of success in sales within life sciences (CRO, eClinical, clinical technology or related)
  • Demonstrable success building and executing territory and account strategies
  • Strong history of delivering revenue growth and exceeding targets
  • Experience managing complex sales cycles, including proposal development and bid leadership
  • Ability to identify pipeline risks and implement mitigation strategies
  • Experience working with CRM platforms, ideally Salesforce
  • Strong proficiency in Microsoft Office (Excel & PowerPoint)
  • Bachelor’s degree in Business, Life Sciences, or related field (MBA preferred)
  • Fluent in English and German
Responsibilities
  • Meet and exceed annual sales targets set by Commercial leadership
  • Own revenue delivery across assigned territory/accounts
  • Build and execute strategic territory and account plans aligned to company growth objectives
  • Identify and pursue high-value opportunities to consistently grow revenue
  • Develop and maintain a strong, qualified sales pipeline
  • Proactively manage pipeline health, risks, and forecasting accuracy
  • Collaborate with Lead Generation and senior Commercial stakeholders to identify and pursue new opportunities
  • Lead strategic client engagement from initial approach through to deal close
  • Own proposal strategy, including narrative development and executive positioning
  • Lead bid pursuit processes, governance meetings, and cross-functional deal teams
  • Build strong, long-term relationships to establish preferred supplier status
  • Drive account expansion through strategic account planning
  • Identify opportunities to increase wallet share within existing clients
  • Work with Strategic Marketing and internal teams to introduce new eClinical offerings into the market
  • Support successful go-to-market execution for new capabilities
Desired Qualifications
  • MBA preferred

Generate a clear, concise company summary for Perceptive based on the provided description.

Company Size

1,001-5,000

Company Stage

Late Stage VC

Total Funding

$15M

Headquarters

New Haven, Connecticut

Founded

2000

Get referred to Perceptive

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Alpha-emitting oncology programs are expanding, and Perceptive targets this fast-growing niche.
  • The January 2026 $15M investment adds two-site At-211 infrastructure in the U.S. and U.K.
  • Exclusive MH3D service-provider status strengthens Perceptive's positioning with radiopharmaceutical sponsors.

What critics are saying

  • CapVest owns Perceptive after the 2025 Calyx acquisition, limiting strategic independence.
  • Ennov bought Calyx Enterprise Technology in February 2024, shrinking Perceptive's software breadth.
  • Perceptive now depends on radiopharmaceutical demand and MH3D execution for α-Sight™ adoption.

What makes Perceptive unique

  • Perceptive Discovery launched α-Sight™ with MH3D on April 15, 2026 for alpha imaging.
  • Perceptive invested $15M on January 8, 2026 to expand radiochemistry and At-211 capabilities.
  • Perceptive combines imaging, radiochemistry, VivoQuant™, and preclinical workflows across oncology and CNS.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Remote Work Options

Health Savings Account/Flexible Spending Account

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Fertility Treatment Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Adoption Assistance

Paid Holidays

Parental Leave

Education allowance

Tuition Reimbursement

Meal Benefits

Cycle to work scheme

Season ticket loan

Cycle to work scheme

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
PR Newswire
Apr 15th, 2026
Perceptive Discovery partners with MH3D to launch α-Sight™ for alpha radiopharmaceutical imaging

Perceptive Discovery has partnered with MH3D to launch α-Sight™, a preclinical imaging service for visualising alpha-emitting radiopharmaceuticals. The offering addresses imaging limitations in alpha-emitting therapies, which are increasingly used in oncology, by providing high-sensitivity, quantitative whole-body imaging. α-Sight™ combines MH3D's Alpha-SPECT™ Mini platform with Perceptive Discovery's expertise in preclinical imaging and radiochemistry. The service supports multi-isotope imaging for therapies using Actinium-225 and Astatine-211, integrated with VivoQuant™ for advanced analysis. Perceptive Discovery will serve as MH3D's exclusive service provider whilst collaborating on product enhancements. The platform supports biodistribution studies, tumour targeting validation and pharmacokinetic assessment to accelerate radioligand therapy development.

PR Newswire
Jan 8th, 2026
Perceptive Discovery secures $15M to expand radiochemistry and cell assay capabilities

Perceptive Discovery, the preclinical services division of Perceptive, has announced $15 million in strategic investments from shareholder CapVest Partners to expand its radiochemistry, cell assay and in vitro biology capabilities. The funding will support development services for oncology and radiopharmaceutical programmes from discovery through early clinical translation. The investment will significantly expand Perceptive Discovery's Astatine-211 infrastructure globally across two sites in the US and UK. The new facilities will feature specialised research environments and dedicated scientific personnel to support At-211 labelling, method development and preclinical applications. The investment underscores CapVest's confidence in Perceptive Discovery's business potential and reinforces the company's commitment to delivering integrated, high-quality preclinical workflows for drug development programmes.

INACTIVE